Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prognostic Differences in Subgroups of Patients With Surgically Resected T3 Non-Small Cell Lung Cancer  Jae Hyun Jeon, MD, Moon Soo Kim, MD, Duk Hwan.

Published byAndrew Atkinson Modified over 5 years ago

Similar presentations

Presentation on theme: "Prognostic Differences in Subgroups of Patients With Surgically Resected T3 Non-Small Cell Lung Cancer  Jae Hyun Jeon, MD, Moon Soo Kim, MD, Duk Hwan."— Presentation transcript:

1 Prognostic Differences in Subgroups of Patients With Surgically Resected T3 Non-Small Cell Lung Cancer  Jae Hyun Jeon, MD, Moon Soo Kim, MD, Duk Hwan Moon, MD, Hee Chul Yang, MD, Bin Hwangbo, MD, PhD, Hyae Young Kim, MD, PhD, Jong Mog Lee, MD, Geon-Kook Lee, MD, PhD  The Annals of Thoracic Surgery  Volume 102, Issue 5, Pages (November 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 The number of bronchoplastic procedures in the group with tumor invading main bronchus within 2 cm of the carina during the study period. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Disease-free survival (A) and overall survival curves (B) according to the T3 descriptors in all patients. (T3-cent = tumor invading main bronchus within 2 cm of the carina; T3-comb = tumor with combined T3 descriptors; T3-inv = tumor invading beyond visceral pleura; T3-sep = separate tumor nodules; T3-size = tumor larger than 7 cm.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Disease-free survival (A) and overall survival curves (B) according to the T3 descriptors in N0 patients. (T3-cent = tumor invading main bronchus within 2 cm of the carina; T3-comb = tumor with combined T3 descriptors; T3-inv = tumor invading beyond visceral pleura; T3-sep = separate tumor nodules; T3-size = tumor larger than 7 cm.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Disease-free survival (A) and overall survival curves (B) according to the operative methods in the group with tumor invading main bronchus within 2 cm of the carina. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Prognostic Differences in Subgroups of Patients With Surgically Resected T3 Non-Small Cell Lung Cancer  Jae Hyun Jeon, MD, Moon Soo Kim, MD, Duk Hwan."

Similar presentations

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Thymic Epithelial Tumors: Prognostic Determinants Among Clinical, Histopathologic, and Computed Tomography Findings  Jung Won Moon, MD, Kyung Soo Lee,

Thymic Epithelial Tumors: Prognostic Determinants Among Clinical, Histopathologic, and Computed Tomography Findings  Jung Won Moon, MD, Kyung Soo Lee,
Repeated Target Vessel Revascularization After Coronary Artery Bypass for In-Stent Restenosis  Jung-Hwan Kim, MD, Seung Hyun Lee, MD, PhD, Hyun-Chel Joo,

Repeated Target Vessel Revascularization After Coronary Artery Bypass for In-Stent Restenosis  Jung-Hwan Kim, MD, Seung Hyun Lee, MD, PhD, Hyun-Chel Joo,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer  Pierre-Benoit Pagès, MD, Pierre Mordant,

History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer  Pierre-Benoit Pagès, MD, Pierre Mordant,
Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Fate of Newly Detected Lesions During Postoperative Surveillance for Non-Small Cell Lung Cancer  Jae-Ik Lee, MD, PhD, Young-Jin Lee, RN, Kook-Yang Park,

Fate of Newly Detected Lesions During Postoperative Surveillance for Non-Small Cell Lung Cancer  Jae-Ik Lee, MD, PhD, Young-Jin Lee, RN, Kook-Yang Park,
Solitary Fibrous Tumors of the Pleura: Surgical Outcome and Clinical Course  Sook Hwan Sung, MD, Jee-Won Chang, MD, Jhingook Kim, MD, Kyung Soo Lee, MD,

Solitary Fibrous Tumors of the Pleura: Surgical Outcome and Clinical Course  Sook Hwan Sung, MD, Jee-Won Chang, MD, Jhingook Kim, MD, Kyung Soo Lee, MD,
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.
Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer  José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,

Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer  José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,
The Annals of Thoracic Surgery

The Annals of Thoracic Surgery
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Similar presentations

Ads by Google